Atea Pharmaceuticals, Inc. (AVIR)
5.47
-0.04
(-0.73%)
USD |
NASDAQ |
Aug 27, 15:58
Atea Pharmaceuticals Enterprise Value : 222.89M for Aug. 26, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 26, 2026 | 222.89M |
| August 25, 2026 | 216.47M |
| August 24, 2026 | 222.89M |
| August 21, 2026 | 216.47M |
| August 20, 2026 | 210.86M |
| August 19, 2026 | 229.30M |
| August 18, 2026 | 204.44M |
| August 17, 2026 | 199.63M |
| August 14, 2026 | 191.61M |
| August 13, 2026 | 187.60M |
| August 12, 2026 | 186.79M |
| August 11, 2026 | 185.99M |
| August 10, 2026 | 183.59M |
| August 07, 2026 | 202.03M |
| August 06, 2026 | 181.18M |
| August 05, 2026 | 161.93M |
| August 04, 2026 | 157.92M |
| August 03, 2026 | 150.70M |
| July 31, 2026 | 157.92M |
| July 30, 2026 | 161.13M |
| July 29, 2026 | 151.50M |
| July 28, 2026 | 142.68M |
| July 27, 2026 | 167.55M |
| July 24, 2026 | 160.33M |
| July 23, 2026 | 161.93M |
| Date | Value |
|---|---|
| July 22, 2026 | 166.74M |
| July 21, 2026 | 171.56M |
| July 20, 2026 | 163.94M |
| July 17, 2026 | 171.56M |
| July 16, 2026 | 159.12M |
| July 15, 2026 | 170.75M |
| July 14, 2026 | 157.92M |
| July 13, 2026 | 161.13M |
| July 10, 2026 | 181.18M |
| July 09, 2026 | 174.76M |
| July 08, 2026 | 166.74M |
| July 07, 2026 | 172.36M |
| July 06, 2026 | 171.56M |
| July 02, 2026 | 180.38M |
| July 01, 2026 | 164.34M |
| June 30, 2026 | 153.91M |
| June 29, 2026 | 113.55M |
| June 26, 2026 | 103.95M |
| June 25, 2026 | 92.75M |
| June 24, 2026 | 103.15M |
| June 23, 2026 | 103.15M |
| June 22, 2026 | 95.95M |
| June 18, 2026 | 93.55M |
| June 17, 2026 | 91.15M |
| June 16, 2026 | 85.54M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Filana Therapeutics, Inc. | -38.03M |
| CorMedix, Inc. | 539.43M |
| Eloxx Pharmaceuticals, Inc. | 12.83M |
| Cannabis Global, Inc. | -- |
| Breakthrough Chemistry, Inc. | 1.389M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.93M |
| Total Expenses (Quarterly) | 32.93M |
| EPS Diluted (Quarterly) | -0.4114 |
| Earnings Yield | -38.23% |
| Normalized Earnings Yield | -38.23 |